Faculty Highlight: Mark Wentland
Mark Wentland began his career in drug discovery in 1970 when he joined the medicinal chemistry department at Sterling Winthrop Inc. During his 24 years at Sterling Winthrop, he held various scientific and administrative leadership positions and was also Adjunct Professor of Chemistry at Rensselaer Polytechnic Institute where he taught over 30 graduate-level organic and medicinal chemistry courses. In 1994, he joined the chemistry faculty at Rensselaer as Professor of Chemistry. Following his retirement at the end of 2015, he was appointed to the position of Professor Emeritus. Since 1997, he holds the concurrent position of Adjunct Professor - Center for Neuropharmacology & Neuroscience at Albany Medical College where his responsibilities include collaborative neuroscience research with AMC scientists and presentation of lectures relating to medicinal chemistry.
Samidorphan - Discovery of a Medication Currently in Multiple Phase 3 Clinical Trials: At Rensselaer, Professor Wentland led several NIH-funded research programs in medicinal chemistry aimed at identifying novel, long-acting oral agents to treat central nervous system disorders. This research resulted in four drugs entering clinical trials, including samidorphan, a medication currently in multiple Phase 3 trials.